Search results for "Community-Acquired Pneumonia"
showing 10 items of 51 documents
Antibiotic Use Prior To Admission And Community Acquired Pneumonia (CAP)
2011
Validation Of Ecurb In Community-Acquired Pneumonia: Which Gold Standard Are We Talking About?
2011
Accuracy Of Non-Invasive Methods For The Evaluation Of Oxygenation Status In Community-Acquired Pneumonia: Comparison Of PaO2/FiO2 Calculated From Se…
2012
Community Acquired Pneumonia (CAP) With PSI V Admitted To Intensive Care Unit (ICU). Comparative Study
2010
Long-term Prognostic Value Of CURB-65 In Community-acquired Pneumonia
2010
Community acquired pneumonia in children: Treatment of complicated cases and risk patients. Consensus statement by the Spanish Society of Paediatric …
2015
The incidence of community-acquired pneumonia complications has increased during the last decade. According to the records from several countries, empyema and necrotising pneumonia became more frequent during the last few years. The optimal therapeutic approach for such conditions is still controversial. Both pharmacological management (antimicrobials and fibrinolysis), and surgical management (pleural drainage and video-assisted thoracoscopic surgery), are the subject of continuous assessment. In this paper, the Spanish Society of Paediatric Infectious Diseases and the Spanish Society of Paediatric Chest Diseases have reviewed the available evidence. Consensus treatment guidelines are prop…
Consensus document on community-acquired pneumonia in children. SENP-SEPAR-SEIP
2020
Community-acquired pneumonia (CAP) is a prevalent disease among children and is frequently associated with both diagnostic and therapeutic uncertainties. Consensus has been reached between SEPAR, SENP and SEIP, and their conclusions are as follows.
Community acquired pneumonia in children: Outpatient treatment and prevention
2015
There have been significant changes in community acquired pneumonia (CAP) in children in the last decade. These changes are related to epidemiology and clinical presentation. Resistance to antibiotics is also a changing issue. These all have to be considered when treating Community acquired pneumonia (CAP). In this document, two of the main Spanish pediatric societies involved in the treatment of CAP in children, propose a consensus concerning therapeutic approach. These societies are the Spanish Society of Paediatric Infectious Diseases and the Spanish Society of Paediatric Chest Diseases. The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP) has also been …
Early and late cardiovascular events in patients hospitalized for community-acquired pneumonia
2020
Abstract Introduction Community-acquired pneumonia increases the risk of cardiovascular events (CVE). The objective of this study was to analyze host, severity, and etiology factors associated with the appearance of early and late events and their impact on mortality. Method Prospective multicenter cohort study in patients hospitalized for pneumonia. CVE and mortality rates were collected at admission, 30-day follow-up (early events), and one-year follow-up (late events). Results In total, 202 of 1967 (10.42%) patients presented early CVE and 122 (6.64%) late events; 16% of 1-year mortality was attributed to cardiovascular disease. The host risk factors related to cardiovascular complicatio…
Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac)
2020
Community-acquired pneumonia (CAP) remains the first cause of morbidity and mortality worldwide due to infection. Several aspects such as severity and host response are related to its clinical course and outcome. Beyond the acute implications that the infection provokes in the host, pneumonia also has long-term negative consequences. Among them, cardiovascular complications and mortality are the most outstanding. Therefore, an adequate recognition and stratification of the risk of complications and mortality is crucial. Many biomarkers have been studied for these reasons, considering that each biomarker mirrors a different aspect. Moreover, the clinical application of many of them is still …